Loss of Endocan tumorigenic properties after alternative splicing of exon 2

详细信息    查看全文

• 作者：Florence Depontieu (1) (2)
  Bogdan-Dragos Grigoriu (1) (2) (3)
  Arnaud Scherpereel (1) (2) (4)
  Estelle Adam (1) (2)
  Maryse Delehedde (1) (2)
  Philippe Gosset (1) (2)
  Philippe Lassalle (1) (2)
  
• 刊名：BMC Cancer
• 出版年：2008
• 出版时间：December 2008
• 年：2008
• 卷：8
• 期：1
• 全文大小：557KB
• 参考文献：1. Seljelid R, Jozefowski S, Sveinbjornsson B: Tumor stroma. / Anticancer Res 1999, 19 (6A) : 4809-822.
  2. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. / Nature 2000, 407 (6801) : 249-57. CrossRef
  3. Hanahan D, Weinberg RA: The hallmarks of cancer. / Cell 2000, 100 (1) : 57-0. CrossRef
  4. Bouck N, Stellmach V, Hsu SC: How tumors become angiogenic. / Adv Cancer Res 1996, 69: 135-74. CrossRef
  5. Strieter RM, Polverini PJ, Arenberg DA, Walz A, Opdenakker G, Van Damme J, Kunkel SL: Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. / J Leukoc Biol 1995, 57 (5) : 752-62.
  6. Turley EA: Proteoglycans and cell adhesion. Their putative role during tumorigenesis. / Cancer Metastasis Rev 1984, 3 (4) : 325-39. CrossRef
  7. Tumova S, Woods A, Couchman JR: Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. / Int J Biochem Cell Biol 2000, 32 (3) : 269-88. CrossRef
  8. Perrimon N, Bernfield M: Specificities of heparan sulphate proteoglycans in developmental processes. / Nature 2000, 404 (6779) : 725-28. CrossRef
  9. Park PW, Reizes O, Bernfield M: Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. / J Biol Chem 2000, 275 (39) : 29923-9926. CrossRef
  10. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR: Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. / Nat Med 1999, 5 (7) : 803-09. CrossRef
  11. Delehedde M, Lyon M, Sergeant N, Rahmoune H, Fernig DG: Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland. / J Mammary Gland Biol Neoplasia 2001, 6 (3) : 253-73. CrossRef
  12. Bechard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, Vazeux R, Richet C, Degand P, Jude B, Janin A, Fernig DG, Tonnel AB, Lassalle P: Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. / J Biol Chem 2001, 276 (51) : 48341-8349.
  13. Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, Janin A, Tonnel A, Lassalle P: Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. / J Vasc Res 2000, 37 (5) : 417-25. CrossRef
  14. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, Jourdain M, Pugin J, Tonnel AB, Lassalle P: Endocan, a new endothelial marker in human sepsis. / Crit Care Med 2006, 34 (2) : 532-37. CrossRef
  15. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, Devos R, Tonnel AB: ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. / J Biol Chem 1996, 271 (34) : 20458-0464. CrossRef
  16. Tsai JC, Zhang J, Minami T, Voland C, Zhao S, Yi X, Lassalle P, Oettgen P, Aird WC: Cloning and characterization of the human lung endothelial-cell-specific molecule-1 promoter. / J Vasc Res 2002, 39 (2) : 148-59. CrossRef
  17. Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, Tsicopoulos A, Plenat F, Bechard D, Tonnel AB, Lassalle P: Overexpression of endocan induces tumor formation. / Cancer Res 2003, 63 (18) : 6084-089.
  18. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. / Nature 2002, 415 (6871) : 530-36. CrossRef
  19. Borczuk AC, Shah L, Pearson GD, Walter KL, Wang L, Austin JH, Friedman RA, Powell CA: Molecular signatures in biopsy specimens of lung cancer. / Am J Respir Crit Care Med 2004, 170 (2) : 167-74. CrossRef
  20. Glinskii A, Hoffman R, Gerald W, Glinsky G, Kimmel S: GeneChip analysis reveals multiple clinically relevant genetic signatures of metastatic prostate cancer: Washington. / (Edited by: Research AAC). American Association for Cancer Research 2003, 44: Abstract Number: LB-106.
  21. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte JJ, Copin MC, Tonnel AB, Lassalle P: Endocan expression and relationship with survival in human non-small cell lung cancer. / Clin Cancer Res 2006, 12 (15) : 4575-582. CrossRef
  22. Aitkenhead M, Wang SJ, Nakatsu MN, Mestas J, Heard C, Hughes CC: Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. / Microvasc Res 2002, 63 (2) : 159-71. CrossRef
  23. Venables JP: Aberrant and alternative splicing in cancer. / Cancer Res 2004, 64 (21) : 7647-654. CrossRef
  24. Brinkman BM: Splice variants as cancer biomarkers. / Clin Biochem 2004, 37 (7) : 584-94. CrossRef
  25. Lassalle P, Delneste Y, Gosset P, Wallaert B, Tonnel AB, Dessaint JP, Capron A: Neutrophil-endothelial cell interaction: evidence in vitro for a regulation by endothelial cells of neutrophil functions. / Eur Respir J 1991, 4 (10) : 1251-257.
  26. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. / CA Cancer J Clin 2006, 56 (2) : 106-30. CrossRef
  27. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF: Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. / BMC Cancer 2003, 3 (1) : 31. CrossRef
  28. Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A, Dekan G, Vogl S, Kubista E, Heider KH, Stratowa C, Schreiber M, Sommergruber W: Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. / Cancer Res 2004, 64 (3) : 844-56. CrossRef
  29. Hayes GM, Dougherty ST, Davis PD, Dougherty GJ: Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expression. / Cancer Gene Ther 2004, 11 (12) : 797-07. CrossRef
  30. Hendrix MJ, Seftor EA, Hess AR, Seftor RE: Molecular plasticity of human melanoma cells. / Oncogene 2003, 22 (20) : 3070-075. CrossRef
  31. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/14/prepub
  
• 作者单位：Florence Depontieu (1) (2)
  Bogdan-Dragos Grigoriu (1) (2) (3)
  Arnaud Scherpereel (1) (2) (4)
  Estelle Adam (1) (2)
  Maryse Delehedde (1) (2)
  Philippe Gosset (1) (2)
  Philippe Lassalle (1) (2)
  
  1. INSERM U774, 59019, Lille, France
  2. Pasteur Institute, 59019, Lille, France
  3. University of Medicine and Pharmacy, 700111, Iasi, Romania
  4. Clinique des Maladies Respiratoires, H?pital A Calmette, CHRU, 59037, Lille, France
  
• ISSN：1471-2407

文摘

Background Endocan was originally described as a dermatan sulfate proteoglycan found freely circulating in the blood. Endocan expression confers tumorigenic properties to epithelial cell lines or accelerate the growth of already tumorigenic cells. This molecule is the product of a single gene composed of 3 exons. Previous data showed that endocan mRNA is subject to alternative splicing with possible generation of two protein products. In the present study we identified, and functionally characterized, the alternative spliced product of the endocan gene: the exon 2-deleted endocan, called endocanΔ2. Methods Stable, endocanΔ2-overexpressing cell lines were generated to investigate the biological activities of this new alternatively spliced product of endocan gene. Tumorigenesis was studied by inoculating endocan and endocanΔ2 expressing cell lines subcutaneously in SCID mice. Biochemical properties of endocan and endocanΔ2 were studied after production of recombinant proteins in various cell lines of human and murine origin. Results Our results showed that the exon 2 deletion impairs synthesis of the glycan chain, known to be involved in the pro-tumoral effect of endocan. EndocanΔ2 did not promote tumor formation by 293 cells implanted in the skin of severe combined immunodeficient (SCID) mice. Conclusion Our results emphasize the key role of the polypeptide sequence encoded by the exon 2 of endocan gene in tumorigenesis, and suggest that this sequence could be a target for future therapies against cancer.